Table I. Immunology of NZB/W F1 mice treated from week 13 with irinotecan compared with saline-treated controls
Saline25 mg/kg Irinotecan50 mg/kg Irinotecan
Spleen cell populations
  B220+ cells (%)32.89 ± 3.3122.17 ± 2.32*20.95 ± 3.89***
  IgMlowIgDlow B cells (%)9.79 ± 3.7214.25 ± 4.6511.13 ± 3.59
  IgG-producing B cells (ELISPOTs per 106 cells)5497 ± 38131787 ± 1703**479 ± 602**
  CD4+/CD8+ ratio4.79 ± 2.22.34 ± 0.43**2.09 ± 0.25**
  CD69+ CD4 cells (%)6.01 ± 1.564.03 ± 1.13**3.13 ± 0.77***
  CD11b+ cells (%)1.73 ± 0482.64 ± 1.472.24 ± 0.32
Neutrophils from peripheral blood (103/mm3)0.40 ± 0.370.42 ± 0.210.34 ± 0.17
IgG anti-ds DNA (A405–490 nm)2.01 ± 0.672.31 ± 0.501.29 ± 0.63
Total IgG (mg/ml)9.87 ± 4.8213.99 ± 5.3912.72 ± 6.77
  • Saline-treated control mice were sacrificed when they had reached proteinuria grade 4+ and weight loss >25% calculated from the beginning of the disease (n = 6). The mean age of saline-treated animals was 39 wk. Irinotecan-treated animals were sacrificed at week 50/51 (n = 6, both groups).

  • * p < 0.05; **p < 0.01; ***p < 0.001.